Memantine extended release (ER) significantly outperformed placebo on co-primary endpoints of Clinician’s Interview-based Impression of Change Plus Caregiver Input (CIBIC-Plus) and baseline to endpoint changes on the Severe Impairment Battery (SIB) in a 24-week, randomized trial
(NCT00322153) in patients with moderate to severe Alzheimer’s disease taking a cholinesterase inhibitor (ChEI). A post hoc analysis compared patients receiving memantine ER/ChEI to placebo/ChEI for time to onset of response and if the response was maintained (achieving improvement at
weeks 8, 12, or 18 and maintaining through endpoint/week 24) on the SIB, the Neuropsychiatric Inventory (NPI), CIBIC-Plus, and Activities of Daily Living (ADL) using Fisher exact test. A second post hoc analysis compared percentages of patients for all possible combinations of 2 to 4 assessments
with either no decline or clinically notable response using Wald χ2. Significantly greater percentages of memantine ER/ChEI patients achieved an early response that was maintained on SIB, NPI, and CIBIC-Plus (P<0.05) versus placebo/ChEI. Significantly greater percentages
of memantine ER/ChEI-treated patients achieved and maintained a clinically notable response on ADL/NPI, SIB/ADL/NPI, and SIB/ADL/CIBIC-Plus, compared with placebo/ChEI (P<0.05). Memantine ER results in early, maintained improvement in patients with moderate to severe Alzheimer’s
disease concurrently taking ChEIs, compared with cholinesterase treatment alone.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
Activities of Daily Living;
Severe Impairment Battery;
Document Type: Research Article
Department of Psychiatry and Behavioral Neuroscience, Division of Geriatric Psychiatry, Saint Louis University, Saint Louis, MO
ATP Clinical Research, Costa Mesa, CA
Pentara Corporation, Salt Lake City, UT
Prescott Medical Communications Group, Chicago, IL
Allergan PLC, Madison, NJ
July 1, 2018